Market News How it works Learn FAQ
| GPUS 0.1689 34.05% | XXII 0.1977 -8.34% | SHFS 0.1324 -61.39% | NVD 4.19 0.96% | LUCD 0.411 25.42% | SPCX 147.49 1.89% | T 20.93 -7.96% | SOXL 83.56 1.77% | NU 15.16 2.92% | NOK 8.14 3.30% | EWZ 42.59 1.77% | NVDA 210.96 -0.59% | RIME 0.106 -12.90% | INTC 86.96 1.72% | TSLG 4.87 -1.62% | AAL 12.11 -3.89% | BBD 4.07 3.04% | STLA 4.06 -4.81% | SOXS 52.46 -1.85% | RWM 14.55 0.34% | HYG 77.05 -0.06% | MYND 0.24 47.42% | BITO 10.83 -0.28% | SPDN 8.54 0.47% | YFOR 0.2236 -1.58% | RBNE 0.19 -2.56% | TQQQ 66.29 -0.20% | VZ 44.66 -1.19% | TSLL 9.76 -1.21% | SPTI 27.63 -0.11% | YMAT 2.05 6.77% | CRWV 54.235 -2.46% | INFY 12.35 -6.58% | RIG 6.41 5.43% | F 11.6 -2.85% | SQQQ 39.68 0.20% | AIOK 12.02 182.82% | ONDS 6.2 2.99% | AAPL 347.725 -0.14% | LABT 0.31 -36.67% | CDE 13.45 -3.10% | PCG 12.63 -2.70% | GRAB 2.79 -2.11% | SOFI 14.615 -1.05% | XLE 69.33 2.60% | IREN 24.905 -2.37% | QID 14.55 0.14% | RKT 11.73 -0.09% | WULF 11.32 0.00% | BE 193.3 -11.24%
PFPfizer Inc. logo

Pfizer Inc. (PFE)

New York Stock Exchange · Currency in USD
$30.03 ▼ -0.39 (-1.28%)
At close: Oct 23, 4:02 PM ET. Market closed.
$30.02 ▼ -0.01 (-0.03%)
After hours: Oct 23, 7:54 PM ET

Summary

Previous Close
$30.42
Open
$30.30
Day's Range
$29.81 – $30.32
52 Week Range
$23.62 – $30.44
Volume
29,400,028
Avg. Volume
38,588,829
Market Cap
$171.16B
Beta (5Y Monthly)
0.28
PE Ratio (TTM)
39.68
EPS (TTM)
$0.76
Earnings Date
Nov 3, 2026
Forward Dividend & Yield
$1.72 (5.73%)
Ex-Dividend Date
Nov 6, 2026
1y Target Est
$29.17

Profile: Pfizer Inc.

Sector
Healthcare
Industry
Drug Manufacturers - General
Full-time employees
75,000
CEO
Albert Bourla
Website
pfizer.com

Pfizer Inc. is a global biopharmaceutical leader engaged in the research, development, production, marketing, and distribution of a wide array of medicinal and vaccine products worldwide. Its comprehensive portfolio addresses diverse therapeutic areas, including cardiovascular health and women's health, featuring key brands such as the Premarin family and Eliquis. The company also offers advanced biologics, small molecule drugs, immunotherapies, and biosimilars for various conditions, exemplified by Ibrance, Xtandi, and Retacrit.

Earnings

Next report: Tue, Nov 3, 2026
EPS estimate $0.73 · Revenue est. $15.86B
DateEst.Actual
Aug 4, 2026$0.68$0.77Beat
May 5, 2026$0.72$0.75Beat
Feb 3, 2026$0.57$0.66Beat
Nov 4, 2025$0.63$0.87Beat
Aug 5, 2025$0.58$0.78Beat
Apr 29, 2025$0.67$0.92Beat

Analyst view

Consensus price target
$29.17 ▼ -2.9%
Range $26.00 – $33.00
Rating: Hold
Buy 40% · Hold 58% · Sell 3%

Get free alerts on PFE and big market moves

Free special alerts by text & email on new investment opportunities, buyouts and the stocks moving most, in plain English.
Get free stock alerts →
Data: Financial Modeling Prep. For information only, not investment advice.